Jump to content

Tranylcypromine/trifluoperazine

From Wikipedia, the free encyclopedia
Tranylcypromine/trifluoperaizne
Combination of
TranylcypromineMonoamine oxidase inhibitor
TrifluoperazineTypical antipsychotic
Clinical data
Trade namesParstelin, Parmodalin, Jatrosom N, Stelapar
Routes of
administration
Oral
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number

Tranylcypromine/trifluoperazine (brand names Parstelin, Parmodalin, Jatrosom N, Stelapar) is a combination formulation of the monoamine oxidase inhibitor antidepressant drug tranylcypromine and the typical antipsychotic drug trifluoperazine that has been used in the treatment of major depressive disorder.[1][2][3] It contains 10 mg tranylcypromine and 1 mg trifluoperazine.[3][4] The drug has been in clinical use since at least 1961.[3]

It may come to assume a certain place in the treatment of borderline personality disorder.[5]

See also

[edit]

References

[edit]
  1. ^ Dart RC (2004). "Monoamine Oxidase Inhibitors". Medical Toxicology. Lippincott Williams & Wilkins. pp. 825–. ISBN 978-0-7817-2845-4.
  2. ^ Stahl SM (15 May 2014). Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. pp. 783–. ISBN 978-1-107-67502-5.
  3. ^ a b c Straker M, Grauer H (July 1961). "Clinical Study of a Potent Antidepressant, Tranylcypromine with Trifluorperazine (Parstelin ), in the Aged Chronically Ill". Canadian Medical Association Journal. 85 (3): 127–130. PMC 1848140. PMID 20326829.
  4. ^ Kalinowsky LB, Hippius H, Klein HE (1982). Biological Treatments in Psychiatry. Grune and Stratton, Harcourt Brace Jovanovich. ISBN 978-0-8089-1423-5.
  5. ^ Cowdry, R. W., & Gardner, D. L. (1988). Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of general psychiatry, 45(2), 111–119. https://doi.org/10.1001/archpsyc.1988.01800260015002